<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946539</url>
  </required_header>
  <id_info>
    <org_study_id>83045809-604.01.02</org_study_id>
    <nct_id>NCT04946539</nct_id>
  </id_info>
  <brief_title>Value of Ultrasonographic Enthesitis Assessment in Spondyloarthritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine how valuable ultrasonographic enthesitis to asssess&#xD;
      disease activity, functionality and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease activity,</measure>
    <time_frame>between November 2016 and January 2017</time_frame>
    <description>BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), minimum value 0, maximum value 10, higher scores mean a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity,</measure>
    <time_frame>between November 2016 and January 2017</time_frame>
    <description>Ankylosing Spondylitis Disease Activity Score (ASDAS). It is calculated by adding CRP (ASDAS-CRP) or ESR (ASDAS-ESR). there is no spesific minimal and maximum value because it depends on CRP or ESR value. Higher scores mean a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functionality</measure>
    <time_frame>between November 2016 and January 2017</time_frame>
    <description>Bath Ankylosing Spondylitis Functionality Index (BASFI). Minimal values 0, maximum value 100. Higher scores mean a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to measure quality of life</measure>
    <time_frame>between November 2016 and January 2017</time_frame>
    <description>Short Form - 12 (SF-12). minimum value 0 maximum value 100. higher scores mean a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to measure quality of life</measure>
    <time_frame>between November 2016 and January 2017</time_frame>
    <description>Ankylosing Spondylitis Quality of Life (ASQoL). minimum value 0 maximum value 18. Higher scores mean a worse outcome</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">97</enrollment>
  <condition>Spondyloarthritis</condition>
  <condition>Enthesitis</condition>
  <arm_group>
    <arm_group_label>Spondyloarthritis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasonography</intervention_name>
    <description>Enthesitis assessment via ultrasonography</description>
    <arm_group_label>Spondyloarthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Spondyloarthritis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Spondyloarthritis patients that fulfill 2009 ASAS criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of elbow, ankle or knee surgery, local injection at the examination sites&#xD;
             within the six weeks, peripheral neuropathy, infection and wound at examination site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization</investigator_affiliation>
    <investigator_full_name>Gunay ER</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

